RxDoctor Payments Data

Carlos Espinoza, MD

Cardiovascular Disease · Rocky Mount, NCNPI 1073827176

Payments from drug & device makers

$4,366in general payments, 2019–2025

Across 114 payments — averaging $38.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$495
  • Cardiovascular Systems Inc.$265
  • Abbott$262
  • Novartis$221
  • Medtronic$165
  • plus $847 from 19 others

What the payments were for

  • Travel & lodging$2,19650%
  • Food & beverage$2,17050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,366 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$79,529
Medicare patients
480
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$227,252
EntrestoSacubitril/Valsartan148$100,022
XareltoRivaroxaban119$88,265
BrilintaTicagrelor125$73,826
JardianceEmpagliflozin22$22,660
Repatha SureclickEvolocumab31$20,418
FarxigaDapagliflozin Propanediol12$13,413
Praluent PenAlirocumab18$8,764
Metoprolol Succinate346$3,202
Ranolazine ErRanolazine33$2,919
Prasugrel Hcl61$2,536
Atorvastatin Calcium203$2,087
Amiodarone Hcl66$1,577
Isosorbide Mononitrate ErIsosorbide Mononitrate178$1,565
ClopidogrelClopidogrel Bisulfate193$1,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$227,252321 claims
NovartisEntresto$221$100,022148 claims
Johnson & JohnsonXarelto$59$88,265119 claims
AstraZenecaBrilinta, Farxiga$82$87,239137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →